APA (7th ed.) Citation

A, M., F, C., MK, D., M, F., P, G., JD, G., . . . MS, M. (2026). Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. Circulation. Heart failure, 19(6), e014205. https://doi.org/10.1161/CIRCHEARTFAILURE.126.014205

Chicago Style (17th ed.) Citation

A, Masri, et al. "Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy." Circulation. Heart Failure 19, no. 6 (2026): e014205. https://doi.org/10.1161/CIRCHEARTFAILURE.126.014205.

MLA (9th ed.) Citation

A, Masri, et al. "Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy." Circulation. Heart Failure, vol. 19, no. 6, 2026, p. e014205, https://doi.org/10.1161/CIRCHEARTFAILURE.126.014205.